MEDIF - MediPharm Labs Breaks Free From Royalty Agreement What It Means & What's Next | Benzinga
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) has executed a supplementary agreement to its asset purchase agreement with 1193269 B.C. Ltd., operating as Shelter Cannabis for the Shelter Cannabis Brands IP portfolio, ending any ongoing royalty payments after August 31, 2023.
Under the existing asset purchase agreement, executed in March 2022, MediPharm Labs purchased the IP of Shelter Cannabis Brands. This IP has been focused in the market on Wildlife Cannabis domestic dry flower and pre-roll products that are manufactured and distributed via the MediPharm sites.
Why It Matters
The supplementary agreement allows for an improvement in this product line's gross margin, providing ...